Jones J L
Int J Technol Assess Health Care. 1998 Summer;14(3):567-72. doi: 10.1017/s0266462300011533.
This article highlights factors that may cause bias in individual controlled trials or meta-analysis of zidovudine (AZT) in HIV disease. The overall benefit of AZT and antiretroviral drug combinations in the progression of HIV disease is probably greater than has been or can ever be shown in an ethical controlled trial.
本文强调了可能导致齐多夫定(AZT)治疗HIV疾病的个体对照试验或荟萃分析出现偏差的因素。在HIV疾病进展方面,AZT及抗逆转录病毒药物组合的总体益处可能大于在符合伦理的对照试验中已经显示或可能显示的益处。